 ChromaDex Corp. NASDAQ:CDXC today announced the 11th published human trial on its patented NAD-boosting nutrient Niagen, further highlighting its potential to support cardiovascular health in humans. A NIH funded study by Cardiology Division and Mitochondria Metabolism Center at the University of Washington, published in The Journal of Clinical Investigation, found that Niagen supplementation reduced signs of inflammation, specifically inflammatory cytokines in vivo, in a small group of end-stage heart failure patients. A second arm of the study, conducted ex vivo, found improved mitochondrial respiration and reduced inflammatory factor expressions in peripheral blood mononuclear cells PBMCs isolated from human subjects and treated with nicotinamide riboside. 